Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
OBJECTIVE
To describe the results obtained in 25 males with metastatic castration-resistant prostate cancer (MCRPC) treated with abiraterone (AA). A comparative analysis of abiraterone effectiveness and safety between our results and data published in the literature was conducted.


METHODS
Bi-institutional prospective analysis of 25 consecutive patients with MCRPC undergoing treatment with abiraterone, with a mean follow-up 7.9 (3-15) months was carried out. Treatment effectiveness and safety analyses regarding baseline characteristics of patients (age, prior treatments, basal PSA, performance status, pain, metastasis) were conducted.


RESULTS
At 13.6 months of follow-up, the overall survival is 80% (CI 95%: 11.8-15.4). Clinical and radiological-free progression survival is 9.5 ± 1 months (CI 95%: 7.7-11.3) and biochemical response is 6.8 ± 1 months (CI 95%: 5-8.7). Only the treatment with chemotherapy impaired significantly the response time to AA [6.4 months for radiological-free progression survival (CI 95%: 4.2-8,6) and 4.3 months for biochemical-free progression survival (CI 95%: 2.6-6)]. The incidence of adverse drug events was 36%, all of them grade 1-2/4 and, in no case, suspension or reduction of the dose of AA was needed.


CONCLUSIONS
The treatment with AA has been effective in our series, with a tolerability considerably higher than what other studies published.
UGC Urología, Hospital de Jerez, Jerez de la Frontera, España. Electronic address: pastora.beardo.sspa@juntadeandalucia.es.
P
P
Beardo-Villar
UGC Urología, Hospital Puerta del Mar, Cádiz, España.
M J
MJ
Ledo-Cepero
UGC Farmacia, Hospital de Jerez, Jerez de la Frontera, España.
R
R
Gavira-Moreno
UGC Urología, Hospital de Jerez, Jerez de la Frontera, España.
M
M
Soto-Delgado
UGC Urología, Hospital Puerta del Mar, Cádiz, España.
J
J
Soto-Villalba
UGC Urología, Hospital Puerta del Mar, Cádiz, España.
J L
JL
Alvarez-Ossorio
UGC Urología, Hospital de Jerez, Jerez de la Frontera, España.
A
A
Juárez-Soto
D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000069501:Abiraterone Acetate
17α-hidroxilasa; 17α-hydroxylase; Abiraterona acetato; Abiraterone acetate; CYP17; Cáncer de próstata resistente a la castración; Metastatic castration-resistant prostate cancer; New hormonal therapies; Nuevas terapias hormonales; Secondary hormonal therapy; Terapia hormonal secundaria